This meeting is supported by:

OVERVIEW

RAS GTPases are among the most critical drivers of oncogenic signalling. This online meeting convenes industry and academic experts from the US and Europe to explore strategies for targeting RAS across medicinal chemistry, protein–protein interactions (PPIs), and clinical translation.

We will examine how RAS structure, mutations, and interaction partners inform drug design, highlighting advances in direct inhibitors and novel modalities, including covalent, allosteric, molecular glue and degrader approaches..

Confirmed speakers are:

• John Taylor (Cancer Research Horizons)
• Natalia Karolak (Prof. Alessio Ciulli's laboratory, University of Dundee)
• Veronika Ehmke (Novartis; SHOC2)
• Adrian Gill (Revolution Medicines)
• Ryan Wurtz (Amgen)
• Matt Patricelli (Vividion)
• Frank McCormick (UC San Francisco)

More information to follow